Научно-практическая ревматология

Расширенный поиск

Запретный плод: каннабиноиды в ревматологической практике

Полный текст:

Список литературы

1. <div><p>Перечень наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации (утв. постановлением Правительства РФ от 30 июня 1998 г. № 681) (с изменениями от 8 июля 2006 г., 4 июля 2007 г., 22 июня 2009 г.).</p><p>Turcotte D., Le Dorze J., Esfahani F. et al. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother 2010; 11(1): 17-31.</p><p>Elikkottil J., Gupta P., Gupta K. The analgesic potential of cannabinoids. J Opioid Manag 2009, 5(6): 341-57.</p><p>Shaladi A., Crestani F., Tartari S., Piva B. Cannabinoids in the control of pain. Recenti Prog Med 20084; 99(12): 616-24.</p><p>Dray A., Read S. Arthritis and pain. Future targets to control osteoarthritis pain. Arthr Res Ther 2007; 9(3): 212.</p><p>Aggarwal S., Carter G., Sullivan M. et al. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag 2009; 5(3): 153-68.</p><p>Zuardi A. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006; 28(2): 153-7.</p><p>Pertwee R. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147(S1): 163-71.</p><p>Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 2001; 178: 107-15.</p><p>&lt;;</p><p>&lt;;</p><p>&lt;; William_Brooke_O%27Shaughnessy</p><p>&lt;; Joseph_Moreau</p><p>Guindon J., Hohmann A. The Endocannabinoid System and Pain. CNS Neurol Disord Drug Targets 2009; 8(6): 403-21.</p><p>Beltramo M. Cannabinoid type 2 receptor as a target for chronic pain. Mini Rev Med Chem 2009; 9(1): 11-25.</p><p>Telleria-Diaz A., Schmidt M., Kreusch S. et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. Pain 2010; 148(1): 26-35.</p><p>Schuelert N., McDougall J. Cannabinoid-mediated antinociception is enhanced in rat osteoarthritic knees. Arthr Rheum 2008; 58(1): 145-53.</p><p>Richardson D., Pearson R., Kurian N. et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthr Res Ther 2008; 10(2): 43.</p><p>Cohen P. Medical marijuana: the conflict between scientific evidence and political ideology. Part one of two. J Pain Palliat Care Pharmacother 2009; 23(1): 4-25.</p><p>Karst M., Wippermann S. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective. Expert Opin Investig Drugs 2009; 18(2): 125-33.</p><p>McPartland J., Russo E. Cannabis and cannabis extracts: greater than the sum of their parts? J Cannabis Ther 2001; 1: 103-32.</p><p> &lt;;</p><p>Гринспун Л., Бакалар Д., Марихуана: запретное лекарство. Пер. с англ. М.В. Кривенюк; Под ред. К.В. Жвакина. М.: Ультра. Культура, 2003; 432 с.</p><p>Cotter J. Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic Literature Review. Oncol Nurs Forum 2009; 36(3): 345-52.</p><p>Davis M. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 2008; 17(1): 85-95.</p><p>Tramer M., Carroll D., Campbell F. et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323(7303): 16-21.</p><p>Юрьев К.Л., Антоненко Г.Г. Эндогенная каннабиноидная система - новый перспективный объект фармакотерапевтического воздействия при болезнях нервной системы? Український медичний часопис 2005; 6(50): 21-9.</p><p>Cabral G., Griffin-Thomas L. Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease. Endocr Metab Immune Disord Drug Targets 2008; 8(3): 159-72.</p><p>Romero J., Martinez-Orgado J. Cannabinoids and neurodegenerative diseases. CNS Neurol Disord Drug Targets 2009; 8(6): 440-50.</p><p>Wade D., Collin C., Stott C., Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010; 16(6): 707-14.</p><p>Iskedjian M., Bereza B., Gordon A. et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007; 23(1): 17-24.</p><p>Zajicek J., Fox P., Sanders H. et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-26.</p><p>Wilsey B., Marcotte T., Tsodikov A. et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9(6): 506-21.</p><p>Ellis R., Toperoff W., Vaida F. et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34(3): 672-80.</p><p>Ware M., Adams H., Guy G. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005; 59: 291-5.</p><p>Aggarwal S., Carter G., Sullivan M. et al. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag 2009; 5(5): 257-86.</p><p>Reisfield G., Wasan A., Jamison R. The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med 2009; 10(8): 1434-41.</p><p>Wallace M., Schulteis G., Atkinson J. et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007; 107(5): 785-96.</p><p>Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006; 53(8): 769-75.</p><p>Johnson J., Burnell-Nugent M., Lossignol D. et al. Multicenter, doubleblind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010; 39(2): 167-79.</p><p>Martin-Sanchez E., Furukawa T., Taylor J., Martin J. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009; 10(8): 1353-68.</p><p>Pinsger M., Schimetta W., Volc D. et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain - a randomized controlled trial. Wien Klin Wschr 2006; 118(11-12): 327-35.</p><p>Blake D., Robson P., Ho M. et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006; 45: 50-2.</p><p>Russo E. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 2008; 29(2): 192-200.</p><p>Schley M., Legler A., Skopp G. et al. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006; 22(7): 1269-76.</p><p>Ablin J., Buskila D. Emerging therapies for fibromyalgia: an update. Expert Opin Emerg Drugs 2010; 15(3): 521-33.</p><p>Skrabek R., Galimova L., Ethans K., Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9(2): 164-173.</p><p>Ware M., Fitzcharles M., Joseph L., Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110(2): 604-10.</p><p>Weber J., Schley M., Casutt M. et al. Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey. Anesthesiol Res Pract 2009; 2009. pii: 827290.</p><p>Wang T., Collet J., Shapiro S., Ware M. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008; 178(13): 1669-78.</p><p>Mazzoncini R., Donoghue K., Hart J. et al. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr Scand 2010; 121(5): 351-8.</p><p>Moore T., Zammit S., Lingford-Hughes A. et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370(9584): 319-28.</p><p>Radbruch L., Nauck F. A review of side effects and complications with cannabinoid treatment. Schmerz 2003; 17(4): 274-9.</p><p>Pesce A., West C., Rosenthal M. et al. Marijuana correlates with use of other illicit drugs in a pain patient population. Pain Physician 2010; 13(3): 283-7.</p><p>Ware M., St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010; 105(3): 494-503.</p><p>Cooper Z., Haney M. Actions of delta- 9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. Int Rev Psychiatry 2009; 21(2): 104-12.</p><p>Zvolensky M., Cougle J., Johnson K. et al. Marijuana use and panic psychopathology among a representative sample of adults. Exp Clin Psychopharmacol 2010; 18(2): 129-34.</p><p>Zeiger J., Haberstick B., Corley R. et al. Subjective effects to marijuana associated with marijuana use in community and clinical subjects. Drug Alcohol Depend 2010; 109(1-3): 161-6.</p></div><br />

Для цитирования:

Каратеев А.Е., Karateyev A.E. Запретный плод: каннабиноиды в ревматологической практике. Научно-практическая ревматология. 2010;48(6):72-79.

For citation:

Karateev A.E., Karateyev A.E. Forbidden fruit: cannabinoids in rheumatological care. Rheumatology Science and Practice. 2010;48(6):72-79. (In Russ.)

Просмотров: 1112

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)